<DOC>
	<DOCNO>NCT01848028</DOCNO>
	<brief_summary>Treatment moderate severe Psoriasis ( Pso ) Psoriasis-Arthritis ( PsA ) largely confine systemic therapy Germany . Systemic therapy include conventional systemic therapy ( e.g . fumaric acid , methotrexate , ciclosporin A ) biological treatment ( e.g . adalimumab , etanercept ) . While short- middle-term efficacy systemic treatment show clinical study ( incorporated international guideline ) , knowledge long-term outcome , optimal treatment effectiveness real-world condition still miss . PsoBest , German registry treatment moderate severe Pso PsA start 2008 document long-term course patient administer biologic conventional systemic antipsoriatic drug authorize Germany first time . The registry evaluate long-term course 3,500 patient Pso PsA treat systemic antipsoriatics .</brief_summary>
	<brief_title>PsoBest - The German Psoriasis Registry</brief_title>
	<detailed_description>Background : Treatment moderate severe Psoriasis ( Pso ) Psoriasis-Arthritis ( PsA ) largely confine systemic therapy Germany . Systemic therapy include conventional systemic therapy ( e.g . fumaric acid , methotrexate , ciclosporin A ) biological treatment ( e.g . adalimumab , etanercept ) . While short- middle-term efficacy systemic treatment show clinical study ( incorporated international guideline ) , knowledge long-term outcome , optimal treatment effectiveness real-world condition still miss . PsoBest , German registry treatment moderate severe Pso PsA start 2008 document long-term course patient administer biologic conventional systemic antipsoriatic drug authorize Germany first time . Objectives : Observation analysis follow outcome treatment systemic antipsoriatics : 1 . Effectiveness clinical practice ( `` real world '' ) 2 . Benefits need patient ' side 3 . Effectiveness long-term course year 4 . Optimal maintenance dosages 5 . Safety side-effects profile routine condition 6 . Use case effect co-morbidity 7 . Reliable predictor response 8 . Benefit effectiveness possible combination therapy alternate use biologics systemic therapy Methods : The registry evaluate long-term course 3,500 patient Pso PsA treat systemic antipsoriatics.The registry start seven treatment arm : Fumaric acid , methotrexate , ciclosporin A , efalizumab , etanercept , infliximab adalimumab . While efalizumab withdrawn market , ustekinumab include authorization . Patients include first initiation give treatment remain registry 5 year , regardless subsequent therapy . Nationwide , dermatologic practice hospital ambulance expertise systemic biologic treatment consecutively enrol patient . Follow-ups every 3 6 month , comprise patient treatment characteristic , clinical parameter , patient-defined benefit , quality life adverse event . Standardized questionnaire address patient dermatologist 12 time dermatologic centre . In interim interval , patient directly contact another 9 time mail . PsoBest member ENCePP network psoriasis-registries ( www.psonet.eu ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>patient diagnosis plaquetype psoriasis psoriasis arthritis confirm dermatologist age â‰¥ 18 year administer specific systemic drug first time inform consent participate sufficient language skill ( German ) Exclusion criterion : lack informed consent patient participant clinical trial day admission registry ( patient include clinical trial registry followup , patient data record , analyse separately )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Patient registry</keyword>
	<keyword>Germany</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>psoriatic-arthritis</keyword>
	<keyword>Efalizumab</keyword>
	<keyword>Psonet</keyword>
	<keyword>Effectiveness</keyword>
	<keyword>Safety</keyword>
</DOC>